gefitinib has been researched along with Cancer of Nasopharynx in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, F; Liu, Y; Luo, H; Wu, Y; Zhao, Y | 1 |
| Deng, XB; Jin, ZR; Li, XQ; Liu, QZ; Liu, Y; Ma, L; Miao, XB; Sun, DX; Testa, JR; Wu, Y; Xiao, GH; Yao, KT; Zhang, G | 1 |
| Gu, WG; He, ZR; Huang, Y; Luo, HT; Peng, RJ; Wang, SS; Yuan, ZY | 1 |
| Chan, AT; Chen, H; Cheng, SH; Lo, KW; Lui, VW; Ma, BB; Ng, MH; Poon, FF; Tao, Q; To, KF; Wong, E; Wong, SC | 1 |
| He, BF; Huang, BY; Luo, RC; Sun, AM; Wang, WJ; Zheng, XK | 1 |
| Chan, AT; Cheng, SH; Cheung, CS; Ho, K; Hui, EP; Lau, CP; Lui, VW; Ma, BB; Ng, MH; Ng, PK; Tsao, SW; Tsui, SK | 1 |
| Guan, ZZ; Jiang, WQ; Lin, TY; Wang, SS; Zhang, L | 1 |
| Guan, ZZ; Jiang, WQ; Lin, TY; Wang, SS; Xiang, YQ; Zhang, L | 1 |
| Ahuja, A; Chan, AT; Hui, EP; Kam, M; King, A; Leung, SF; Lo, YM; Ma, B; Mo, F; Mok, T; To, KF; Zee, B | 1 |
| Au, GK; Chua, DT; Nicholls, J; Sham, JS; Wei, WI; Wong, MP | 1 |
2 trial(s) available for gefitinib and Cancer of Nasopharynx
| Article | Year |
|---|---|
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; DNA, Viral; ErbB Receptors; Female; Gefitinib; Herpesvirus 4, Human; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Radiography; Survival | 2008 |
Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
8 other study(ies) available for gefitinib and Cancer of Nasopharynx
| Article | Year |
|---|---|
Construction of EGFR peptide gefitinib/quantum dots long circulating polymeric liposomes for treatment and detection of nasopharyngeal carcinoma.
Topics: Antineoplastic Agents; Carcinoma; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gefitinib; Humans; Liposomes; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides; Polymers; Quantum Dots; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cisplatin; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanog Homeobox Protein; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Quinazolines; Side-Population Cells; Signal Transduction; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cisplatin; Drug Synergism; Female; Flow Cytometry; Gefitinib; Heterografts; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Quinazolines; Tumor Cells, Cultured | 2013 |
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Pharmacological; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[Gefitinib enhances the radiosensitivity of nasopharyngeal carcinoma cell line CNE2 in vitro].
Topics: Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Gefitinib; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Quinazolines; Radiation Tolerance | 2011 |
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Synergism; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines | 2013 |
[Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor ZD1839 on nasopharyngeal carcinoma cells].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Fluorouracil; G1 Phase; Gefitinib; Humans; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2004 |
[Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts].
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cisplatin; Drug Synergism; ErbB Receptors; Female; Gefitinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Random Allocation | 2004 |